Inhibitor Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-3.3	-3.34	-3.03	12.11	-0.3	Upgrade
Stock-Based Compensation	0.02	0.04	0.01	-	0.04	Upgrade
Other Operating Activities	0	-	-	-0.51	-0.04	Upgrade
Change in Accounts Payable	0.03	0.04	0.4	0.14	0.05	Upgrade
Change in Other Net Operating Assets	0.02	0.02	-0.09	0	0.03	Upgrade
Operating Cash Flow	-3.23	-3.23	-2.7	11.74	-0.22	Upgrade
Long-Term Debt Issued	-	-	-	0.18	0.18	Upgrade
Long-Term Debt Repaid	-	-	-0.41	-	-	Upgrade
Net Debt Issued (Repaid)	-	-	-0.41	0.18	0.18	Upgrade
Financing Cash Flow	-	-	-0.41	0.18	0.18	Upgrade
Net Cash Flow	-3.23	-3.23	-3.11	11.92	-0.04	Upgrade
Levered Free Cash Flow	-2.07	-2.18	-1.8	-0.6	-0.12	Upgrade
Unlevered Free Cash Flow	-2.07	-2.18	-1.8	-0.59	-0.11	Upgrade
Change in Working Capital	0.04	0.07	0.31	0.14	0.08	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.